# US 2026/0125703 A1 · Adapter-based retroviral vector system for the selective transduction of target cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0125703 A1
- Document ID: US20260125703A1
- Status: Published application
- Kind: A1
- Application number: 19/251,540
- Filed: 2025-06-26
- Published: 2026-05-07
- Earliest claimed: 2017-10-30
- Assignees: Miltenyi Biotec GmbH
- Applicants: Miltenyi Biotec B.V. & Co. KG
- Inventors: Thomas Schaser; Nicole Cordes; Joerg Mittelstaet; Andrew Kaiser
- Web page: https://patentgrep.com/patent/US20260125703A1

## CPC

- C12N 15/86: Viral vectors
- C07K 14/005: from viruses
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/01: containing a localisation/targetting motif
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2740/10045: Special targeting system for viral vectors
- C12N 2740/16045: Special targeting system for viral vectors
- C12N 2760/18022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/18422: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2810/859: from immunoglobulins
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This disclosure provides a composition comprising i) a pseudotyped retroviral vector particle or virus-like particle thereof comprising a) one envelope protein with antigen-binding activity, wherein said envelope protein is a recombinant protein that does not interact with at least one of its native receptor(s) and is fused at its ectodomain to a polypeptide comprising an antigen binding domain specific for a tag of a tagged polypeptide, and wherein said envelope protein is protein G, HN or H derived from the Paramyxoviridae family, and b) one envelope protein with fusion activity derived from the Paramyxoviridae family, and ii) said tagged polypeptide, wherein said tagged polypeptide binds specifically to an antigen expressed on the surface of a target cell, thereby transducing the target cell with said retroviral vector particle or thereby inducing uptake of the virus-like particle into the target cell. A pharmaceutical composition thereof and an in vitro method for transduction of targets cells with said vector particle are also disclosed.

## Claims

### Claim 1

(canceled)

### Claim 2

A combination of reagents configured for delivery of a gene or protein to a target cell, wherein the combination consists of:
(i) a tagged polypeptide that comprises a means for binding specifically to an antigen on the target cell; and
(ii) a pseudotyped Paramyxoviridae viral vector that contains said gene or protein;
wherein the pseudotyped Paramyxoviridae viral vector is a lentiviral or gammaretroviral vector that comprises:
(a) a Paramyxoviridae attachment protein that has been genetically modified to replace constitutive cell binding activity with a means for binding specifically to said tagged polypeptide, and
(b) a Paramyxoviridae fusion (F) protein that has fusion activity;
wherein said attachment protein is a Morbillivirus hemagglutinin (H) or a Henipavirus glycoprotein (G);
wherein contacting the target cell with said Paramyxoviridae viral vector in the presence of said tagged polypeptide results in delivery of said gene or protein into the target cell.

### Claim 3 (depends on 2)

The reagent combination of claim 2, wherein said means for binding on the Paramyxoviridae attachment (H or G) protein is a single-chain antibody that binds specifically to said tagged polypeptide.

### Claim 4 (depends on 2)

The reagent combination of claim 2, wherein said means for binding on the tagged polypeptide comprises a single domain antibody, a diabody, an Fab fragment, an Fab′ fragment, or a single-chain antibody that binds specifically to said antigen on the target cell.

### Claim 5 (depends on 2)

The reagent combination of claim 2, wherein said modified Paramyxoviridae attachment (H or G) protein and/or said Paramyxoviridae fusion (F) protein lacks at least part of its cytoplasmic region.

### Claim 6 (depends on 2)

The combination according to claim 2, wherein the pseudotyped Paramyxoviridae viral vector is configured for gene delivery to the target cell.

### Claim 7 (depends on 2)

The combination according to claim 2, wherein the pseudotyped Paramyxoviridae viral vector is configured for protein delivery to the target cell.

### Claim 8 (depends on 2)

The reagent combination of claim 2 wherein said fusion (F) protein is from the same Paramyxoviridae genus as said attachment (H or G) protein.

### Claim 9 (depends on 2)

The reagent combination of claim 2, wherein said Paramyxoviridae is a measles virus.

### Claim 10 (depends on 2)

The reagent combination of claim 2, wherein said means for binding on the Paramyxoviridae attachment (H or G) protein binds specifically to an epitope on the tagged polypeptide that is not expressed on any human cell located at or around where said target cell is contacted with said Paramyxoviridae viral vector in the presence of said tagged polypeptide.

### Claim 11 (depends on 2)

The reagent combination of claim 2, wherein said means for binding on the Paramyxoviridae attachment (H or G) protein binds specifically to an epitope on the tagged polypeptide that is not a small-molecule hapten.

### Claim 12 (depends on 2)

The reagent combination of claim 2, wherein said means for binding on the modified Paramyxoviridae attachment protein binds with at least 10-fold higher affinity to said tagged polypeptide than to a polypeptide without a tag.

### Claim 13 (depends on 2)

The reagent combination of claim 2, wherein in the presence of the tagged polypeptide, delivery of the gene or the protein to the target cell by the viral vector is at least 10-fold higher than to non-target cells.

### Claim 14 (depends on 2)

The reagent combination of claim 2, formulated together in a single pharmaceutical composition that further comprises one or more physiologically acceptable carriers or excipients.

### Claim 15

A method for delivering a gene or protein to a target cell, comprising:
(1) obtaining a pseudotyped Paramyxoviridae viral vector that encapsulates said gene or protein, wherein the pseudotyped Paramyxoviridae viral vector is a lentiviral or gammaretroviral vector that comprises:
(a) a Paramyxoviridae attachment protein that has been genetically modified to replace constitutive cell binding activity with binding activity for a tagged polypeptide, and
(b) a Paramyxoviridae fusion (F) protein that has fusion activity;
wherein said attachment protein is a Morbillivirus hemagglutinin (H) or a Henipavirus glycoprotein (G):
(2) contacting the target cell with said pseudotyped Paramyxoviridae viral vector in the presence of a tagged polypeptide that binds to an antigen on the target cell;
whereby said gene or protein is delivered by the pseudotyped Paramyxoviridae viral vector to the target cell.

### Claim 16 (depends on 15)

The method of claim 15, wherein the target cells are preincubated with the tagged polypeptide before being contacted with the pseudotyped Paramyxoviridae viral vector.

### Claim 17 (depends on 15)

The method of claim 15, wherein said tagged polypeptide comprises a single domain antibody, a diabody, an Fab fragment, an Fab′ fragment, or a single-chain antibody that binds specifically to said antigen on the target cell.

### Claim 18 (depends on 15)

The method of claim 15, wherein said Paramyxoviridae attachment (H or G) protein binds specifically to an epitope on the tagged polypeptide that is not expressed on any human cell located at or around where said target cell is contacted with said Paramyxoviridae viral vector in the presence of said tagged polypeptide.

### Claim 19 (depends on 15)

The method of claim 15, wherein said Paramyxoviridae attachment (H or G) protein binds specifically to an epitope on the tagged polypeptide that is not a small-molecule hapten.

### Claim 20 (depends on 15)

The method of claim 15, wherein said modified Paramyxoviridae attachment protein binds with at least 10-fold higher affinity to said tagged polypeptide than to a polypeptide without a tag.

### Claim 21 (depends on 15)

The method of claim 15, wherein in the presence of the tagged polypeptide, delivery of the gene or the protein to the target cell by the viral vector is at least 10-fold higher than to non-target cells.
